Lantern Pharma Newsroom

Press Release: Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 P.m. ET

Dow JonesAug 1 08:14 ET

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)

TipRanksMay 10 06:26 ET

Lantern Pharma Analyst Ratings

BenzingaApr 25 06:41 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Lantern Pharma (LTRN), LifeMD (LFMD) and Calliditas Therapeutics (CALT)

TipRanksNov 9, 2023 07:02 ET

EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

BenzingaAug 10, 2023 07:16 ET

Lantern Pharma Analyst Ratings

BenzingaAug 10, 2023 07:15 ET

Lantern Pharma (LTRN) Receives a Hold From H.C. Wainwright

TipRanksAug 10, 2023 06:25 ET

Analysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Lantern Pharma (LTRN)

TipRanksJun 26, 2023 16:30 ET

EF Hutton Assumes Lantern Pharma at Buy, Maintains Price Target of $11

BenzingaMay 25, 2023 08:26 ET

EF Hutton Reaffirms Their Buy Rating on Lantern Pharma (LTRN)

TipRanksMar 21, 2023 12:28 ET

EF Hutton Sticks to Their Buy Rating for Lantern Pharma (LTRN)

TipRanksFeb 15, 2023 11:30 ET

Lantern Pharma Analyst Ratings

Benzinga Analyst RatingsFeb 15, 2023 11:05 ET

EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

Benzinga Real-time NewsFeb 15, 2023 11:05 ET

Lantern Pharma Analyst Ratings

Benzinga Analyst RatingsNov 1, 2022 04:56 ET

EF Hutton Initiates Coverage On Lantern Pharma With Buy Rating, Announces Price Target of $11

Benzinga Real-time NewsNov 1, 2022 04:56 ET